28 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
or products that we may develop; termination of clinical trials; withdrawal of marketing approval, product recall, restriction on the approval or a “black … as they occur. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes
ARS
d60 o6rurfc
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
en4yf35cfj8wf95ollm
18 Apr 23
Preliminary proxy
7:59am
424B4
lc4vcs8v1ekoul
21 Jun 21
Prospectus supplement with pricing info
8:08am
DRS
758pyn265g
19 May 21
Draft registration statement
12:00am